Juhienah K Khalaf1, William S Bowen2, Hélène G Bazin1, Kendal T Ryter1, Mark T Livesay1, Jon R Ward1, Jay T Evans1, David A Johnson3. 1. GlaxoSmithKline Vaccines, 553 Old Corvallis Road, Hamilton, MT 59840, USA. 2. Institute for Cellular Therapeutics, University of Louisville School of Medicine, Donald E. Baxter Biomedical Research Building, 570 South Preston Street, Louisville, KY 40202, USA. 3. GlaxoSmithKline Vaccines, 553 Old Corvallis Road, Hamilton, MT 59840, USA. Electronic address: david.a.johnson@gsk.com.
Abstract
TLR4 agonists that favor TRIF-dependent signaling and the induction of type 1 interferons may have potential as vaccine adjuvants with reduced toxicity. CRX-547 (4), a member of the aminoalkyl glucosaminide 4-phosphate (AGP) class of lipid A mimetics possessing three (R)-3-decanoyloxytetradecanoyl groups and d-relative configuration in the aglycon, selectively reduces MyD88-dependent signaling resulting in TRIF-selective signaling, whereas the corresponding secondary ether lipid 6a containing (R)-3-decyloxytetradecanoyl groups does not. In order to determine which secondary acyl groups are important for the reduction in MyD88-dependent signaling activity of 4, the six possible ester/ether hybrid derivatives of 4 and 6a were synthesized and evaluated for their ability to induce NF-κB in a HEK293 cell reporter assay. An (R)-3-decanoyloxytetradecanoyl group on the 3-position of the d-glucosamine unit was found to be indispensable for maintaining low NF-κB activity irrespective of the substitutions (decyl or decanoyl) on the other two secondary positions. These results suggest that the carbonyl group of the 3-secondary lipid chain may impede homodimerization and/or conformational changes in the TLR4-MD2 complex necessary for MyD88 binding and pro-inflammatory cytokine induction.
TLR4 agonists that favor n class="Gene">TRIF-dependent signaling and the induction of type 1 interferons may have potential as vaccine adjuvants with reduced toxicity. CRX-547 (4), a member of the aminoalkyl glucosaminide 4-phosphate (AGP) class of lipid A mimetics possessing three (R)-3-decanoyloxytetradecanoyl groups and d-relative configuration in the aglycon, selectively reduces MyD88-dependent signaling resulting in TRIF-selective signaling, whereas the corresponding secondary ether lipid 6a containing (R)-3-decyloxytetradecanoyl groups does not. In order to determine which secondary acyl groups are important for the reduction in MyD88-dependent signaling activity of 4, the six possible ester/ether hybrid derivatives of 4 and 6a were synthesized and evaluated for their ability to induce NF-κB in a HEK293 cell reporter assay. An (R)-3-decanoyloxytetradecanoyl group on the 3-position of the d-glucosamine unit was found to be indispensable for maintaining low NF-κB activity irrespective of the substitutions (decyl or decanoyl) on the other two secondary positions. These results suggest that the carbonyl group of the 3-secondary lipid chain may impede homodimerization and/or conformational changes in the TLR4-MD2 complex necessary for MyD88 binding and pro-inflammatory cytokine induction.
Authors: C Lam; E Schütze; J Hildebrandt; H Aschauer; E Liehl; I Macher; P Stütz Journal: Antimicrob Agents Chemother Date: 1991-03 Impact factor: 5.191
Authors: Patrick Garidel; Michael Rappolt; Andra B Schromm; Jörg Howe; Karl Lohner; Jörg Andrä; Michel H J Koch; Klaus Brandenburg Journal: Biochim Biophys Acta Date: 2005-09-15
Authors: Axel G Stöver; Jean Da Silva Correia; Jay T Evans; Christopher W Cluff; Mark W Elliott; Eric W Jeffery; David A Johnson; Michael J Lacy; Jory R Baldridge; Peter Probst; Richard J Ulevitch; David H Persing; Robert M Hershberg Journal: J Biol Chem Date: 2003-10-21 Impact factor: 5.157
Authors: Verónica Mata-Haro; Caglar Cekic; Michael Martin; Paula M Chilton; Carolyn R Casella; Thomas C Mitchell Journal: Science Date: 2007-06-15 Impact factor: 47.728
Authors: Antonio Hernandez; Naeem K Patil; Cody L Stothers; Liming Luan; Margaret A McBride; Allison M Owen; Katherine R Burelbach; David L Williams; Edward R Sherwood; Julia K Bohannon Journal: Pharmacol Res Date: 2019-11-02 Impact factor: 7.658